Abstract
Obesity remains the most pressing unresolved issue of modern medicine. The global population of individuals suffering from obesity, that not only considerably reduces their quality of life, but often leads to disability, increases every year. Moreover, the attitude of modern medicine is as follows: obesity provides the basis for realization of the incidence of polysystemic somatic disorders and cancer, including gynecological disease entities (among which the most strongly associated ones are endometrial hyperplasia and cancer). In this regard, the development of unique promising metabolism-modifying methods of target drug therapy for obesity, which will not only allow one to achieve target body mass index values, but also prevent long-term effects on female health, is most relevant. Tirzepatide, designed for drug treatment of obesity and diabetes mellitus and recently registered in the RF, represents one innovative drug, the key features of which are considered in this paper.
Keywords: obesity, comorbidities, endometrial hyperplasia and cancer, AGLP-1, glucose-dependent insulinotropic polypeptide, tirzepatide.
Keywords: obesity, comorbidities, endometrial hyperplasia and cancer, AGLP-1, glucose-dependent insulinotropic polypeptide, tirzepatide.
For citation: Orazov M.R., Radzinsky V.E., Balan V.E., Dolgov E.D. Drug therapy of obesity in routine realities: tirzepatide efficacy and safety. Clinical review for general practice. 2025; 6 (4): 92–98 (In Russ.). DOI: 10.47407/kr2025.6.4.00600
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
